1-Pentyl-3-phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in mice

Drug and Alcohol Dependence

Volumn 123, Issue 1-3, 2012, Pages 148-153

  Wiley, Jenny L ^a,b   Marusich, Julie A ^a   Martin, Billy R ^b   Huffman, John W ^c,d  

^a RTI INTERNATIONAL   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c CLEMSON UNIVERSITY   (United States)

^d NONE   (United States)

Author keywords

Aminoalkylindoles; Cannabinoid indoles; Herbal incense; Structure activity relationship; Synthetic cannabinoids

Indexed keywords

1 PENTYL 3 PHENYLACETYLINDOLE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; DRONABINOL; NAPHTHALEN 1 YL (1 PENTYLINDOL 3 YL)METHANONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; BINDING AFFINITY; CANNABIS SMOKING; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; HYPOTHERMIA; IN VIVO STUDY; LOCOMOTION; MALE; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING; RECTUM TEMPERATURE; STRUCTURE ACTIVITY RELATION; TAIL FLICK TEST;

CANNABIS; MUS;

EID: 84861225909     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2011.11.001     Document Type: Article

References (39)

1. Atwood B.K., Huffman J., Straiker A., Mackie K. JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br. J. Pharmacol. 2010, 160:585-593.
2. 9-Tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. Neurosci. Biobehav. Rev. 1992, 16:55-62.
3. Barrett R.L., Wiley J.L., Balster R.L., Martin B.R. Pharmacological specificity of delta-9-tetrahydrocannabinol discrimination in rats. Psychopharmacology (Berl.) 1995, 118:419-424.
4. Brents L.K., Reichard E.E., Zimmerman S.M., Moran J.H., Fantegrossi W.E., Prather P.L. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One 2011, 6:e21917.
5. Compton D.R., Gold L.H., Ward S.J., Balster R.L., Martin B.R. Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta-9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 1992, 263:1118-1126.
6. Compton D.R., Johnson M.R., Melvin L.S., Martin B.R. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J. Pharmacol. Exp. Ther. 1992, 260:201-209.
7. Compton D.R., Rice K.C., De Costa B.R., Razdan R.K., Melvin L.S., Johnson M.R., Martin B.R. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J. Pharmacol. Exp. Ther. 1993, 265:218-226.
8. Crocker P.J., Mahadevan A., Wiley J.L., Martin B.R., Razdan R.K. The role of fluorine substitution in the structure-activity relationships (SAR) of classical cannabinoids. Bioorg. Med. Chem. Lett. 2007, 17:1504-1507.
9. D'Ambra T.E., Estep K.G., Bell M.R., Eissenstat M.A., Josef K.A., Ward S.J., Haycock D.A., Baizman E.R., Casiano F.M., Beglin N.C., et al. Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J. Med. Chem. 1992, 35:124-135.
10. Drug Enforcement Administration Schedules of controlled substances: temporary placement of five synthetic cannabinoids into schedule I. Fed. Reg. 2010, 75:71635-71638.
11. Eissenstat M.A., Bell M.R., D'Ambra T.E., Alexander E.J., Daum S., Ackerman J., Gruett M., Kumar V., Estep K.G., Olefirowicz E.M., Wetzel J., Alexander M.D., Weaver J., Haycock D., Luttinger D., Casiano F., Chippari S., Kuster J., Stevenson J., Ward S.J. Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics. J. Med. Chem. 1995, 38:3094-3105.
12. Gaoni Y., Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 1964, 86:1646-1647.
13. Hudson S., Ramsey J. The emergence and analysis of synthetic cannabinoids. Drug Test Anal. 2011, 3:466-478.
14. Huffman J.W. CB2 receptor ligands. Mini Rev. Med. Chem. 2005, 5:641-649.
15. Huffman J.W., Dai D., Martin B.R., Compton D.R. Design, synthesis and pharmacology of cannabimimetic indoles. Bioorg. Med. Chem. Lett. 1994, 4:563-566.
16. Huffman J.W., Mabon R., Wu M.J., Lu J., Hart R., Hurst D.P., Reggio P.H., Wiley J.L., Martin B.R. 3-Indolyl-1-naphthylmethanes: new cannabimimetic indoles provide evidence for aromatic stacking interactions with the CB(1) cannabinoid receptor. Bioorg. Med. Chem. 2003, 11:539-549.
17. Huffman J.W., Padgett L.W. Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes. Curr. Med. Chem. 2005, 12:1395-1411.
18. Huffman J.W., Padgett L.W., Isherwood M.L., Wiley J.L., Martin B.R. 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB(1) and CB(2) receptors. Bioorg. Med. Chem. Lett. 2006, 16:5432-5435.
19. Huffman J.W., Szklennik P.V., Almond A., Bushell K., Selley D.E., He H., Cassidy M.P., Wiley J.L., Martin B.R. 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg. Med. Chem. Lett. 2005, 15:4110-4113.
20. Huffman J.W., Zengin G., Wu M.J., Lu J., Hynd G., Bushell K., Thompson A.L., Bushell S., Tartal C., Hurst D.P., Reggio P.H., Selley D.E., Cassidy M.P., Wiley J.L., Martin B.R. Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists. Bioorg. Med. Chem. 2005, 13:89-112.
21. Järbe T.U., Deng H., Vadivel S.K., Makriyannis A. Cannabinergic aminoalkylindoles, including AM678=JWH018 found in 'Spice', examined using drug (Delta-9-tetrahydrocannabinol) discrimination for rats. Behav. Pharmacol. 2011, 22:498-507.
22. Lindigkeit R., Boehme A., Eiserloh I., Luebbecke M., Wiggermann M., Ernst L., Beuerle T. Spice: a never ending story?. Forensic Sci. Int. 2009, 191:58-63.
23. Manera C., Tuccinardi T., Martinelli A. Indoles and related compounds as cannabinoid ligands. Mini Rev. Med. Chem. 2008, 8:370-387.
24. Martin B.R., Compton D.R., Semus S.F., Lin S., Marciniak G., Grzybowska J., Charalambous A., Makriyannis A. Pharmacological evaluation of iodo and nitro analogs of delta-8-THC and delta-9-THC. Pharmacol. Biochem. Behav. 1993, 46:295-301.
25. Martin B.R., Compton D.R., Thomas B.F., Prescott W.R., Little P.J., Razdan R.K., Johnson M.R., Melvin L.S., Mechoulam R., Ward S.J. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol. Biochem. Behav. 1991, 40:471-478.
26. Martin B.R., Jefferson R., Winckler R., Wiley J.L., Huffman J.W., Crocker P.J., Saha B., Razdan R.K. Manipulation of the tetrahydrocannabinol side chain delineates agonists, partial agonists, and antagonists. J. Pharmacol. Exp. Ther. 1999, 290:1065-1079.
27. National Research Council Guide for the Care and Use of Laboratory Animals 1996, National Academy Press, Washington, DC.
28. Schifano F., Corazza O., Deluca P., Davey Z., Di Furia L., Farre M., Flesland L., Mannonen M., Pagani S., Peltoniemi T., Pezzolesi C., Scherbaum N., Siemann H., Skutle A., Torrens M., Van Der Kreeft P. Psychoactive drug or mystical incense? Overview of the online available information on Spice products. Int. J. Cult. Ment. Health 2009, 2:137-144.
29. Schneir A.B., Cullen J., Ly B.T. " Spice" girls: synthetic cannabinoid intoxication. J. Emerg. Med. 2011, 40:296-299.
30. Showalter V.M., Compton D.R., Martin B.R., Abood M.E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 1996, 278:989-999.
31. Thakur G.A., Nikas S.P., Makriyannis A. CB1 cannabinoid receptor ligands. Mini Rev. Med. Chem. 2005, 5:631-640.
32. Vandrey R., Dunn K.E., Fry J.A., Girling E.R. A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend. 2011, (Epub ahead of print).
33. Vann R.E., Warner J.A., Bushell K., Huffman J.W., Martin B.R., Wiley J.L. Discriminative stimulus properties of delta-9-tetrahydrocannabinol (THC) in C57Bl/6J mice. Eur. J. Pharmacol. 2009, 615:102-107.
34. Vardakou I., Pistos C., Spiliopoulou C. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol. Lett. 2010, 197:157-162.
35. Wiley J.L., Compton D.R., Dai D., Lainton J.A., Phillips M., Huffman J.W., Martin B.R. Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J. Pharmacol. Exp. Ther. 1998, 285:995-1004.
36. Wiley J.L., Huffman J.W., Balster R.L., Martin B.R. Pharmacological specificity of the discriminative stimulus effects of delta-9-tetrahydrocannabinol in rhesus monkeys. Drug Alcohol Depend. 1995, 40:81-86.
37. Wiley J.L., Martin B.R. Cannabinoid pharmacological properties common to other centrally acting drugs. Eur. J. Pharmacol. 2003, 471:185-193.
38. Young A.C., Schwarz E., Medina G., Obafemi A., Feng S.Y., Kane C., Kleinschmidt K. Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Am. J. Emerg. Med. 2011, (July). (Epub ahead of print).
39. Zimmermann U.S., Winkelmann P.R., Pilhatsch M., Nees J.A., Spanagel R., Schulz K. Withdrawal phenomena and dependence syndrome after the consumption of " spice gold" Dtsch. Arztebl. Int. 2009, 106:464-467.